
Agilent Technologies, Inc.
NYSE•A
CEO: Mr. Rodney  Gonsalves
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact Information
Market Cap
$40.65B
P/E (TTM)
33.5
vs Industry 35.8
Dividend Yield (TTM)
0.7%
52W High
$153.84
52W Low
$96.43
52W Range
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9) 
 8-9: Excellent Value
 6-7: Strong Fundamentals
 4-5: Average Quality
 0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$1.74B+10.14% 
4-Quarter Trend
EPS
$1.18+21.65% 
4-Quarter Trend
FCF
$573.00M+59.17% 
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
 CAH
CAH$234.31B
 TAK
TAK$29.98B
 IQV
IQV$15.90B
Gross Margin (Latest Quarter)
77.6%
 TAK
TAK65.2%
64.5%
Key Metrics
| Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets | 
|---|---|---|---|---|
| IDXX | $50.29B | 51.3 | 64.4% | 37.1% | 
| EW | $49.01B | 11.8 | 41.2% | 5.2% | 
| CAH | $45.33B | 28.3 | -55.7% | 16.4% | 
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+0.7%
Moderate Growth
4-Quarter Net Income CAGR
-1.4%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow Performance
Research & Insights
Reports
All Years
- Form 10-Q - Q2 2025Period End: Apr 30, 2025|Filed: Jun 2, 2025|Revenue: $1.67B+6.0%|EPS: $0.75-28.6%Miss
- Form 10-Q - Q1 2025Period End: Jan 31, 2025|Filed: Mar 3, 2025|Revenue: $1.68B+1.4%|EPS: $1.12-5.9%Miss
- Form 10-K - FY 2024Period End: Oct 31, 2024|Filed: Dec 20, 2024|Revenue: $6.51B-4.7%|EPS: $4.44+5.2%Miss
- Form 10-Q - Q3 2024Period End: Jul 31, 2024|Filed: Aug 30, 2024|Revenue: $1.58B-5.6%|EPS: $0.97+155.3%Miss
- Form 10-Q - Q2 2024Period End: Apr 30, 2024|Filed: Jun 3, 2024|Revenue: $1.57B-8.4%|EPS: $1.05+2.9%Miss
- Form 10-Q - Q1 2024Period End: Jan 31, 2024|Filed: Mar 5, 2024|Revenue: $1.66B-5.6%|EPS: $1.19+0.0%Meet
- Form 10-K - FY 2023Period End: Oct 31, 2023|Filed: Dec 20, 2023|Revenue: $6.83B-0.2%|EPS: $4.22+0.7%Miss
- Form 10-Q - Q3 2023Period End: Jul 31, 2023|Filed: Aug 31, 2023|Revenue: $1.67B-2.7%|EPS: $0.38-65.5%Miss